Jupiter Neurosciences wins exclusive U.S. rights to ALA-002

Jupiter Neurosciences on July 22, 2026, signed a definitive agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based candidate with FDA Novel Chemical Entity designation. The deal could be worth up to $100 million and gives Jupiter a second clinical-stage CNS asset alongside its Parkinson’s program.

Why it matters: - The deal turns Jupiter Neurosciences from a single-program biotech into a dual clinical-stage central nervous system company. - ALA-002 gives Jupiter a second development asset in a high-profile psychiatric treatment area. - The agreement also gives Jupiter long-term U.S. commercialization rights if the program reaches market. - The transaction adds diversification alongside Jupiter’s Parkinson’s program and could create multiple near-term clinical and regulatory catalysts.

What happened: - Jupiter Neurosciences signed a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002. - The company announced the deal on July 22, 2026. - Jupiter said the transaction has a potential value of up to $100 million, including milestone payments. - The agreement covers a patented, non-racemic MDMA formulation designated by the U.S. Food and Drug Administration as a Novel Chemical Entity.

The details: - Jupiter will pay $3.3 million upfront, split between $1.5 million in cash and $1.8 million in JUNS common stock with a 120-day lock-up. - Jupiter owes a $3.3 million development milestone if Phase 3 first patient in is reached. - Jupiter owes a $20 million regulatory milestone if the U.S. NDA is approved. - Commercial milestones total $10 million, $30 million and $33.3 million at $333 million, $1 billion and $2 billion in cumulative U.S. net sales. - PharmAla will receive a 3% royalty on net sales after the third commercialization milestone. - ALA-002 has NCE designation from the FDA, which provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - Jupiter said ALA-002 is designed to improve cardiovascular safety and reduce abuse liability versus racemic MDMA while preserving the therapeutic effects associated with MDMA-assisted psychotherapy. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - Jupiter said PharmAla will continue manufacturing ALA-002 drug product under commercial terms to be negotiated. - Jupiter said the arrangement could accelerate development timelines. - The company said the asset targets a U.S. psychedelic therapeutics market estimated at $3 billion in 2024 and $8 billion by 2030. - The release also said the candidate is aimed at treatment-resistant PTSD, anxiety and related neuropsychiatric conditions. - Jupiter’s current lead program, JOTROL, is a proprietary resveratrol formulation in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement. - The company said the agreement was not yet fully closed in the sense that the release includes standard forward-looking statements about closing conditions and execution risks.

Between the lines: - The deal gives Jupiter exposure to the psychedelic medicines space at a time when the company says U.S. regulation is becoming more favorable. - Management is framing the agreement as a portfolio-building move, not just a single-asset license. - The stock component and long-dated milestones suggest both sides are tying value to development progress rather than only upfront cash. - Jupiter also highlighted new board expertise in psychedelic medicines, including Drs. Tomas Philipson and Andrew Cutler, as part of its execution push. - The company’s forward-looking statements point to meaningful clinical, regulatory, financing and manufacturing risks before any commercial payoff. - Jupiter cited the April 18, 2026 executive order on serious mental illness as part of its rationale, but that policy path remains dependent on future FDA and DEA action.

What’s next: - Jupiter will need to advance ALA-002 through clinical development and regulatory review before any milestone-heavy economics can be realized. - PharmAla is expected to keep supplying the drug product while Jupiter negotiates commercial manufacturing terms. - Jupiter said the next 12 months will be transformative, pointing to expected clinical and strategic execution across both CNS programs. - The company will continue pushing JOTROL in Parkinson’s disease while building out the ALA-002 program in the United States.

The bottom line: - Jupiter just bought itself a second shot at value creation in CNS, but the payoff depends on clinical progress, regulatory clearance and funding execution.